AN2 Therapeutics
Clinical-stage biopharmaceutical company developing novel therapeutics for serious and life-threatening infectious diseases, including nontuberculous mycobacterial (NTM) lung disease.
Location
Menlo Park, California, USA
Founded
2018
Investors
1
Categories
biotech, infectious-disease, antibiotics, therapeutics
Notes
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, broad-spectrum therapeutics for serious and life-threatening infectious diseases. The company's lead candidate, epetraborole, is being developed for the treatment of nontuberculous mycobacterial (NTM) lung disease.
Epetraborole is a novel boron-containing antibiotic that targets leucyl-tRNA synthetase, a validated antimicrobial target. The drug has shown potent activity against mycobacteria and is designed to be used in combination with standard-of-care treatments.
Team
- Jake Schwartz - Chief Executive Officer
- LinkedIn: linkedin.com/in/jakeschwartz
- Joshua Kaplan, Ph.D. - Chief Scientific Officer
- Dave Flinois - Chief Financial Officer
Additional Research Findings
- Lead candidate epetraborole for NTM lung disease
- Epetraborole is an oral, once-daily leucyl-tRNA synthetase inhibitor
- Phase 2/3 clinical trials for Mycobacterium avium complex (MAC) lung disease
- FDA Fast Track and Breakthrough Therapy designations
- Backed by leading life sciences investors
- Addressing significant unmet need in NTM treatment
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |